Rezolute (RZLT) Common Equity (2010 - 2026)
Rezolute (RZLT) posted Common Equity of $116.8 million for Q1 2026, down 8.72% sequentially from $128.0 million in Q4 2025, and up 41.5% YoY from $82.6 million in Q1 2025.
Rezolute (RZLT) Common Equity (2010 - 2026) Analysis & Trends
Rezolute has reported Common Equity for 17 years, with the latest figure at $116.8 million in Q1 2026.
- Quarterly Common Equity rose 41.5% year-over-year to $116.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.8 million (up 41.5% YoY) and the FY2025 annual result came in at $162.1 million, up 33.99% from the prior year.
- Common Equity slipped to $116.8 million in Q1 2026 per RZLT's latest filing, from $128.0 million in the prior quarter.
- Over five years, Common Equity peaked at $162.1 million in Q2 2025 and troughed at $51.9 million in Q1 2022.
- A 5-year average of $116.2 million and a median of $116.8 million in 2026 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity soared 610.1% in 2022, then tumbled 44.34% in 2024.
- Over 5 years, Common Equity stood at $141.3 million in 2022, then plunged by 35.07% to $91.7 million in 2023, then climbed by 8.57% to $99.6 million in 2024, then increased by 28.53% to $128.0 million in 2025, then fell by 8.72% to $116.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $116.8 million, $128.0 million, and $147.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - | 116.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.83 Mn |
| Dec 31, 2025 | 128.00 Mn |
| Sep 30, 2025 | 147.17 Mn |
| Jun 30, 2025 | 162.13 Mn |
| Mar 31, 2025 | 82.57 Mn |
| Dec 31, 2024 | 99.59 Mn |
| Sep 30, 2024 | 113.44 Mn |
| Jun 30, 2024 | 121.00 Mn |
| Mar 31, 2024 | 70.86 Mn |
| Dec 31, 2023 | 91.73 Mn |
| Sep 30, 2023 | 103.56 Mn |
| Jun 30, 2023 | 116.17 Mn |
| Mar 31, 2023 | 127.32 Mn |
| Dec 31, 2022 | 141.27 Mn |
| Sep 30, 2022 | 153.09 Mn |
| Jun 30, 2022 | 149.47 Mn |
| Mar 31, 2022 | 51.91 Mn |
| Dec 31, 2021 | 62.27 Mn |
| Sep 30, 2021 | 21.56 Mn |
| Jun 30, 2021 | 26.10 Mn |